GU Cancers Symposium

The PHS290 polygenic hazard score is based on 290 genetic variants linked with prostate cancer risk.

In the phase 2 SWOG 1500 study, cabozantinib (Cabometyx) significantly improved progression-free survival versus sunitinib (Sutent) in patients with metastatic papillary renal cell carcinoma.

Darolutamide is currently approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The immunotherapy/TKI combination significantly improved overall survival versus sunitinib.

Papillary renal cell carcinoma (RCC) is a rare malignancy, accounting for 15% of all RCC cases.

“These findings support the importance of genomic testing to identify patients eligible to consider olaparib treatment,” said Johann de Bono, MB CHB, PhD, MSC.

The FDA is scheduled to decide on a new drug application for tivozanib by March 31, 2021, for use in relapsed/refractory renal cell carcinoma.

The multikinase inhibitor showed significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma and brain metastases.

The combination of the anti–PD-1 immunotherapy and the multikinase inhibitor also extended progression-free survival in the phase 3 KEYNOTE-581/CLEAR trial (Study 307).

Safety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.

The ongoing trial is enrolling patients at 62 locations in the United States and worldwide.

The treatment was also shown to be safe and tolerable in this patient population.

“Among patients treated with apalutamide, molecular signatures indicative of increased immune activity, decreased vascularization, or decreased proliferative capacity at baseline were each independently associated with long-term response,” reported Felix Y. Feng, MD.

Based on findings from the phase 3 CheckMate 9ER trial, the FDA approved nivolumab/cabozantinib for use in the first-line setting for patients with advanced RCC.

The FDA is scheduled to make a decision on a new drug application for 18F-DCFPyL on or before May 28, 2021.

The FDA recently approved a less-frequent, fixed dose of durvalumab at 1500 mg every 4 weeks for use in patients with metastatic urothelial carcinoma.

After adjusting for crossover using a preplanned sensitivity analysis, investigators for the pivotal phase 3 TITAN trial found a 48% reduction in the risk of death in patients treated with apalutamide plus ADT versus ADT alone.

The antibody-drug conjugate was previously granted an accelerated approval by the FDA in this setting based on results from the phase 2 EV-201 trial.

“These findings indicate that darolutamide is an effective and well-tolerated androgen receptor inhibitor as an early treatment option for patients with [nmCRPC],” reported Neal D. Shore, MD.

The novel PSMA-targeted radiopharmaceutical for PET identified M1 disease in the majority of patients examined who otherwise had locoregional disease, according to a subanalysis of the OSPREY trial.

The investigational tubulin inhibitor was also safe and well tolerated at continuous daily dosing.

The higher starting dose of lenvatinib was also associated with a prolonged time to deterioration.

The FDA approved darolutamide in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.

The novel agent eganelisib led to higher response rates with nivolumab in PD-L1–low patients with metastatic urothelial carcinoma.

Determining the optimal treatment approach for patients with non–clear cell renal cell carcinoma has long been an unmet medical need in the field.

With several immunotherapy-based combinations now available in frontline RCC, new options are needed for patients who progress.

There was a trend toward better overall survival outcomes with the apalutamide/abiraterone combination in certain prespecified biomarker subgroups.

Genomics may ultimately play an important role in determining recurrence risk in patients who undergo surgery for localized kidney cancer, according to Brian Rini, MD, of Cleveland Clinic.

Stereotactic body radiotherapy shows rates of acute toxicity that are similar to those of conventionally fractionated radiotherapy in men with low- or intermediate-risk localized prostate cancer, according to early findings from an international randomized study.

While neoadjuvant chemotherapy has been associated with a survival benefit in patients with muscle-invasive bladder cancer, patient selection needs to improve to optimize clinical outcomes and minimize costs, according to Yair Lotan, MD, of the University of Texas Southwestern Medical Center in Dallas.